Ukr.Biochem.J. 2018; Volume 90, Issue 1, Jan-Feb, pp. 58-67

doi: https://doi.org/10.15407/ubj90.01.058

Determination of plasminogen/plasmin system components and indicators of lipoproteins oxidative modification under arterial hypertension

05.02.2018   Uncategorized   No comments

O. I. Yusova1, O. V. Savchuk1, T. V. Grinenko1, O. B. Kuchmenko2, L. S. Mhitaryan2, O. H. Kupchins’ka2, I. N. Yevstratova2, O. O. Matova2, N. M. Vasilinchuk2, T. F. Drobot’ko2

 1Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
e-mail: yusova07@gmail.com;
2SI NSC “Strazhesko Institute of Cardiology”, National Academy of Medical Sciences of Ukraine, Kyiv

The present study was investigated of levels of oxidative modification of lipoproteins and content of plasminogen/plasmin system components – tissue-type plasminogen activator (t-PA) and plasminogen activators inhibitor-1 (PAI-1), in patients with stage II arterial hypertension (AHT) and resistant form of AHT. It was established that t-PA level in blood plasma of the patients is 2 times lower under stage II hypertension than normal and 2.5 times lower under resistant AHT. The inhibitor activity is 1.5 and 2 times higher consequently. It is concluded that patients with AHT have a decreased fibrinolytic potential, which can cause thrombotic states. Our evaluation showed a significant accumulation of products of lipid and protein oxidation, decrease of activity of antioxidant enzymes and changes of the activity of high density-lipoproteins-associated enzymes (decrease of paraoxonase-1 activity, increase of myeloperoxidase activity). Oxidized lipoproteins, t-PA and PAI-1 can be used as prognostic markers of development of complications and for evaluating the efficacy of therapy in patients with arterial hypertension.

Keywords: , , ,

References:

  1. Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014:406960.  PubMed, PubMedCentral, CrossRef
  2. Solak Y, Afsar B, Vaziri ND, Aslan G, Yalcin CE, Covic A, Kanbay M. Hypertension as an autoimmune and inflammatory disease. Hypertens Res. 2016 Aug;39(8):567-73.  PubMed, CrossRef
  3. van der Stoep M, Korporaal SJ, Van Eck M. High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovasc Res. 2014 Aug 1;103(3):362-71. PubMed, CrossRef
  4. Kolev K, Longstaff C. Bleeding related to disturbed fibrinolysis. Br J Haematol. 2016 Oct;175(1):12-23.  PubMed, PubMedCentral, CrossRef
  5. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912-9. PubMed
  6. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost. 2005 Jan;3(1):35-45. PubMed, CrossRef
  7. Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem. 1992 Aug 25;267(24):17128-35. PubMed
  8. Brown NJ. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis. 2010 Oct;4(5):315-24. PubMed, CrossRef
  9. Meade TW, Howarth DJ, Cooper J, MacCallum PK, Stirling Y. Fibrinolytic activity and arterial disease. Lancet. 1994 Jun 4;343(8910):1442. PubMed, CrossRef
  10. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia. 2001 Sep-Oct;3(5):371-84. PubMed, PubMedCentral, CrossRef
  11. Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem. 2008;15(9):923-9. PubMed, CrossRef
  12. Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095-6. PubMed, CrossRef
  13. Varetskaya TV, Loseva AL, Yatsenko VI. On the determination of thrombin activity. Ukr Biokhim Zhurn. 1961;33(5):657-66. (In Ukrainian).  PubMed
  14. Pozdnjakova TM, Musjalkovskaja AA, Ugarova TP, Protvin DD, Kotsjuruba VN. On the properties of fibrin monomer prepared from fibrin clot with acetic acid. Thromb Res. 1979;16(1-2):283-8. PubMed, CrossRef
  15. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680-5.
    PubMed, CrossRef
  16. Kondratiuk AS, Yusova OI, Grynenko TV. Identification of activity of tissue plasminogen activator in blood plasma. Lab Diagnostics. 2011;3(57): 3-9. (In Ukrainian).
  17. Roka-Moya YM, Zhernossekov DD, Kondratyuk AS, Grinenko TV. Development and optimization of the methods for determining activity of plasminogen activator inhibitor-1 in plasma. Ukr Biokhim Zhurn. 2013 Jul-Aug;85(4):111-8. (In Ukrainian). PubMed, CrossRef
  18. Manolescu BN, Berteanu M, Cintezã D. Effect of the nutritional supplement ALAnerv® on the serum PON1 activity in post-acute stroke patients. Pharmacol Rep. 2013;65(3):743-50. PubMed, CrossRef
  19. Gorudko IV, Cherkalina OS, Sokolov AV, Pulina MO, Zakharova ET, Vasil’ev VB, Cherenkevich SN, Panasenko OM. New approaches to the measurement of the concentration and peroxidase activity of myeloperoxidase in human blood plasma. Bioorg Khim. 2009 Sep-Oct;35(5):629-39. (In Russian). PubMed, CrossRef
  20. Kubyshkin AV, Fomochkina II. Elastolytic activity of bronchoalveolar lavage fluid in acute lung inflammatory injury. Ukr Biokhim Zhurn. 2008 Jan-Feb;80(1):89-95. (In Russian). PubMed
  21. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972 May 25;247(10):3170-5. PubMed
  22. Koroliuk MA, Ivanova LI, Mayorova IG, Tokarev VE. A method of determining catalase activity. Lab Delo. 1988;(1):16-9. (In Russian). PubMed
  23. Stalnaya ID, Garishvili TG. Method of determination of malonic dialdehyde with tiobarbituric acid. In the book “Modern methods in biochemistry”/ Ed. V.N. Orekhovich. Moscow: Medicine, 1977. 375 p. (In Russian).
  24. Dubinina EE, Burmistrov SO, Khodov DA, Porotov IG. Oxidative modification of human serum proteins. A method of determining it. Vopr Med Khim. 1995 Jan-Feb;41(1):24-6. (In Russian).  PubMed
  25. Patent 30972А UA  6G 01 N33/48 Method of diagnosis of progressive atherosclerosis / Ievstratova I.N., Mkhitaryan L.S., Orlova N.M., Kasimirko E.I., Fedun N.M., Drobotko T.F. Published on 15.12.2000, Bull. №7. (In Ukrainian).
  26. Klys’ YG, Zajtseva NV, Kizim AI, Verevka SV. Proteolytic derivatives of plasminogen as a factor in malignancy development. Oncology. 2010; 12(1): 17-21. (In Russian).
  27. Chapman MP, Moore EE, Moore HB, Gonzalez E, Gamboni F, Chandler JG, Mitra S, Ghasabyan A, Chin TL, Sauaia A, Banerjee A, Silliman CC. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg. 2016 Jan;80(1):16-25. PubMed, PubMedCentral, CrossRef
  28. Al-Hamodi Z, Ismail IS, Saif-Ali R, Ahmed KA, Muniandy S. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol. 2011 Mar 18;10:23. PubMed, PubMedCentral, CrossRef
  29. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):2019-23. PubMed, CrossRef
  30. Mangge H. Beyond Cholesterol – New Cardiovascular Biomarkers. Nestle Nutr Inst Workshop Ser. 2016;84:81-8.  PubMed
  31. Ramirez A, Hu PP. Low High-Density Lipoprotein and Risk of Myocardial Infarction. Clin Med Insights Cardiol. 2015 Dec 3;9:113-7. PubMed, PubMedCentral, CrossRef
  32. Kovalenko VM, Kuchmenko OB,  Mkhytarian LS. Molecular and genetic peculiarities of the paraoxonase functioning and importance in the development of cardiovascular pathology. Ukr Cardiol J. 2014;(5): 105-116. (In Ukrainian).
  33. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, Fu X, Wagner MA, Besler C, Gerstenecker G, Zhang R, Li XM, DiDonato AJ, Gogonea V, Tang WH, Smith JD, Plow EF, Fox PL, Shih DM, Lusis AJ, Fisher EA, DiDonato JA, Landmesser U, Hazen SL. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest. 2013 Sep;123(9):3815-28. PubMed, PubMedCentral, CrossRef
  34. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm. 2008;2008:135625. PubMed, PubMedCentral, CrossRef
  35. D’Elia JA, Bayliss G, Gleason RE, Weinrauch LA. Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review. Clin Kidney J. 2016 Oct;9(5):705-12. PubMed, PubMedCentral, CrossRef
  36. Olempieva EV. Changes of components of extracellular matrix at hypertonic disease in pregnant and nonpregnant women. Terra Medica. 2013;(4):16-19. (In Russian). 2013; 4: 16-19.
  37. Carbone F, Mach F, Montecucco F. Update on the role of neutrophils in atherosclerotic plaque vulnerability. Curr Drug Targets. 2015;16(4):321-33. PubMed, CrossRef
  38. de Vries MA, Alipour A, Birnie E, Westzaan A, van Santen S, van der Zwan E, Liem AH, van der Meulen N, Cabezas MC. Coronary leukocyte activation in relation to progression of coronary artery disease. Front Med. 2016 Mar;10(1):85-90. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.